Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Down 6.9% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (AMLX) is a biotech company working on developing treatments for various medical conditions, notably avexitide, a drug focused on addressing post-bariatric hypoglycemia. The company is currently engaged in a pivotal Phase 3 clinical trial for avexitide, with significant milestones ahead.

Why is Amylyx Pharmaceuticals going down?

AMLX stock is down 6.9% on May 7, 2026 14:26

• The decline in AMLX stock today could be linked to the anticipation of the company's first-quarter financial results, which are projected to show a per-share loss and no revenue. This financial performance may have disappointed investors.
• Furthermore, the market's reaction to the news about the upcoming Phase 3 LUCIDITY trial data for avexitide, crucial for the company's future valuation and cash position, may have added to the negative sentiment.
• Amylyx Pharmaceuticals' involvement in investor conferences could have also impacted market sentiment, as investors may be waiting for insights or updates from these events before making significant decisions regarding the stock.
• Overall, factors such as financial performance expectations, forthcoming trial data, and participation in investor conferences likely contributed to the bearish movement in AMLX stock today.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Amylyx earnings on deck ahead of pivotal avexitide trial data

Amylyx Pharmaceuticals is set to report first-quarter earnings, with analysts anticipating a loss of 33 cents per share and zero revenue. The financial update precedes critical Phase 3 LUCIDITY trial data for its lead asset, avexitide, later this year, which is crucial for the pre-revenue biotech's cash runway and future valuation. Investors will closely watch operating expenses and cash burn as the company aims to reach its third-quarter milestone without needing additional capital.

https://m.investing.com/news/earnings/amylyx-earnings-on-deck-ahead-of-pivotal-avexitide-trial-data-93CH-4664376?ampMode=1

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals, Inc. announced its participation in two upcoming investor conferences. Management will present at Bank of America’s 2026 Health Care Conference on May 13, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, both featuring fireside chats. Live webcasts of these presentations will be available on the company's investor relations website.

https://www.businesswire.com/news/home/20260506445851/en/Amylyx-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals has launched a U.S. Expanded Access Program (EAP) for adults with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass surgery, providing access to their investigational drug, avexitide. The EAP targets up to 250 eligible individuals who have unmet medical needs and cannot participate in ongoing trials. Avexitide is currently in a pivotal Phase 3 clinical trial (LUCIDITY), with topline data expected in Q3 2026 and potential commercial launch in 2027 if approved.

https://www.biospace.com/press-releases/amylyx-pharmaceuticals-announces-u-s-expanded-access-program-for-adults-with-post-bariatric-hypoglycemia

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals has launched a U.S. Expanded Access Program (EAP) for up to 250 adults with post-bariatric hypoglycemia (PBH) to provide access to avexitide, an investigational GLP-1 receptor antagonist. The program targets patients with unmet medical needs who cannot participate in ongoing trials, while the pivotal Phase 3 LUCIDITY clinical trial for avexitide is ongoing, with topline data expected in Q3 2026. Avexitide, which has Breakthrough Therapy Designation from the FDA, aims to reduce hypoglycemic events by inhibiting exaggerated GLP-1-driven insulin secretion in PBH patients.

https://www.businesswire.com/news/home/20260505966340/en/Amylyx-Pharmaceuticals-Announces-U.S.-Expanded-Access-Program-for-Adults-with-Post-Bariatric-Hypoglycemia

Amylyx Pharmaceuticals (AMLX) Projected to Post Quarterly Earnings on Thursday

Amylyx Pharmaceuticals (AMLX) is expected to report its Q1 2026 earnings before market open on Thursday, May 7th, with analysts forecasting a loss of ($0.32) per share. The company previously beat estimates in its last earnings report. The stock has a market cap of $1.73 billion, and institutional ownership stands at 95.84%, with a "Moderate Buy" consensus rating from analysts.

https://www.marketbeat.com/instant-alerts/amylyx-pharmaceuticals-amlx-projected-to-post-quarterly-earnings-on-thursday-2026-04-30/

Trending Today

Aave ($AAVE) Crypto Forecast: Up 5.2% Today

Amylyx Pharmaceuticals Price History

07.03.2026 - AMLX Stock was up 5.0%

• AMLX shares surged by 6.66% on April 6, driven by positive investor sentiment and analyst recommendations pointing towards a potential upside.
• The 7.8% drop following the earnings report showing $0 revenue and concerns over stock dilution from a shelf filing led to a brief decline in the stock price.
• The completion of enrollment and dosing for the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia is a crucial milestone for AMLX, with the outcome expected to shape the company's future revenue prospects and investment narrative.
• Overall, the bullish movement today can be attributed to a mix of positive analyst outlook, milestone achievements in clinical trials, and short-term market reactions to earnings and dilution concerns.

30.02.2026 - AMLX Stock was down 5.5%

• The bearish movement in AMLX's stock price today can be attributed to a realignment of holdings by a major investment firm, resulting in the firm reporting 0% beneficial ownership of AMLX common stock. This change may have caused uncertainty among investors, leading to a sell-off of the stock.
• Despite analysts on Wall Street maintaining a bullish sentiment on AMLX and reiterating Buy ratings with optimistic price targets, the sudden change in the investment firm's ownership status likely overshadowed these positive recommendations.
• Additionally, the discontinuation of the ORION program for AMX0035, as highlighted in recent SEC filings, could have raised concerns among investors about the company's future pipeline and potential revenue streams, contributing to the bearish market movement.

25.02.2026 - AMLX Stock was up 5.4%

• An investment firm maintains a "Buy" rating for AMLX with a high price target, suggesting a notable potential for growth and enhancing investor confidence.
• The conclusion of enrollment in the crucial Phase 3 LUCIDITY clinical trial for avexitide in post-bariatric hypoglycemia (PBH) demonstrates advancement in a promising treatment, garnering positive attention in the market.
• Amylyx's updated corporate presentation outlining Phase 3 trial progress and strong financial standing, with funds available until 2028, has further encouraged investors.
• The successful completion of patient enrollment in the Phase 3 LUCIDITY trial, alongside positive updates on other research endeavors and a solid financial position, has solidified the market's positive outlook on Amylyx Pharmaceuticals.

29.03.2026 - AMLX Stock was down 5.1%

• The downward movement in AMLX stock today might be due to profit-taking by investors following several price target upgrades by different financial institutions. It is possible that traders decided to sell to secure profits after positive changes were made to the price targets.
• Despite the positive outlook from analysts and the excitement surrounding the Phase 3 LUCIDITY study data for avexitide, the market response today could indicate a short-term decline in the stock price.
• The reduction in the Co-CEO and Director's 2025 compensation compared to the previous year may also play a role in the negative sentiment towards the stock, potentially raising concerns about internal stability or performance expectations within the company.

28.03.2026 - AMLX Stock was down 5.2%

• The bearish movement in AMLX stock today could be attributed to the significant decrease in compensation for both Co-CEOs and Directors, Justin Klee and Joshua Cohen, as revealed in the recent SEC DEF14A filings. This unexpected decrease in executive pay may have raised concerns among investors about the company's financial performance or future prospects.
• Investors might be reacting to the upcoming Q3 2025 earnings preview, anticipating potentially disappointing financial results. The market sentiment could be influenced by expectations set by analysts and insiders' activities.
• Insider trading activities, hedge fund movements, and analyst ratings could have also contributed to the negative market sentiment surrounding AMLX stock, leading to the bearish movement observed today.

28.03.2026 - AMLX Stock was down 5.1%

• An increased price target for AMLX was influenced by a reduced expense forecast, potentially boosting investor confidence initially.
• However, concerns arose over the reduced compensation of the Co-CEO and Director in 2025, prompting doubts about the company's financial well-being and future prospects, leading to the bearish market movement.
• The impending Q3 2025 earnings preview may also be contributing to investor unease and stock selling pressure.
• In summary, despite positive adjustments to the price target, the news about reduced executive compensation and the upcoming earnings report could have dampened optimism, resulting in the decline of AMLX stock.

06.03.2026 - AMLX Stock was up 5.1%

• AMLX experienced a notable 3.52% increase in share price on April 2nd, despite reporting $0 revenue in its recent earnings.
• The positive market response could be linked to the successful enrollment and dosing completion of its pivotal Phase 3 LUCIDITY trial, marking a significant achievement for the company.
• Investor confidence in the potential success of avexitide for post-bariatric hypoglycemia, demonstrated by the trial enrollment completion, likely influenced the bullish movement.
• Concerns about stock dilution after the shelf filing appear to have been outweighed by favorable developments in the company's clinical trials, prompting the upward trend in the stock price.

07.04.2026 - AMLX Stock was down 6.9%

• The decline in AMLX stock today could be linked to the anticipation of the company's first-quarter financial results, which are projected to show a per-share loss and no revenue. This financial performance may have disappointed investors.
• Furthermore, the market's reaction to the news about the upcoming Phase 3 LUCIDITY trial data for avexitide, crucial for the company's future valuation and cash position, may have added to the negative sentiment.
• Amylyx Pharmaceuticals' involvement in investor conferences could have also impacted market sentiment, as investors may be waiting for insights or updates from these events before making significant decisions regarding the stock.
• Overall, factors such as financial performance expectations, forthcoming trial data, and participation in investor conferences likely contributed to the bearish movement in AMLX stock today.

24.02.2026 - AMLX Stock was down 6.1%

• The completion of enrollment in the pivotal Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia (PBH) did not seem to positively impact AMLX's stock performance.
• Despite the positive developments in the clinical trials and the strong cash position of $317 million providing a financial runway into 2028, investors may have had concerns about the company's overall financial performance.
• The market reaction could be attributed to profit-taking by investors who were expecting a more immediate positive impact on the stock price following the enrollment completion and positive trial updates.
• It's possible that the market sentiment was influenced by external factors or broader industry trends affecting biopharmaceutical companies rather than specific news related to Amylyx Pharmaceuticals.

14.03.2026 - AMLX Stock was up 5.3%

• The bullish movement in AMLX stock could be attributed to the selection of AMX0318 as a new development candidate, indicating progress in the company's pipeline for treating neurodegenerative diseases.
• The upcoming presentation at the 25th Annual Needham Virtual Healthcare Conference might have generated positive investor sentiment, as it provides a platform for the company to showcase its innovative therapies and potential market opportunities.
• Despite the investigation into potential breaches of fiduciary duties by insiders, investors seem optimistic about the company's future prospects, possibly due to the focus on addressing diseases with high unmet needs and the positive market analysis reports.
• Overall, the combination of positive corporate developments, upcoming conference presentation, and market analysis highlighting growth potential could have fueled the bullish momentum in AMLX stock today.

10.03.2026 - AMLX Stock was down 5.1%

• The bearish movement in AMLX's stock price could be attributed to the ongoing investigation into potential breaches of fiduciary duties by the company's officers and directors. This uncertainty may have led to a lack of investor confidence in the stock.
• Additionally, despite the positive news of AMLX's participation in the 25th Annual Needham Virtual Healthcare Conference to showcase its development candidates, the market may have reacted negatively to the lack of concrete updates or significant announcements during the event.
• The insider trading activities disclosed in the SEC filings, including stock sales for tax obligations and gifts, might have also contributed to the downward pressure on AMLX's stock price as investors may interpret these actions as a lack of long-term confidence in the company's prospects.
• Overall, the combination of legal investigations, lack of significant updates from the healthcare conference, and insider trading activities could have collectively influenced the bearish market movement in AMLX today.

17.03.2026 - AMLX Stock was up 5.4%

• Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) received a "Moderate Buy" recommendation from brokerages, indicating positive sentiment towards the stock.
• The company reported quarterly earnings that slightly beat analyst estimates, contributing to the bullish movement in the stock.
• Insider transactions, such as recent sales by the CEO, and adjustments in holdings by institutional investors may have influenced market confidence in the company's future prospects, driving the bullish movement in the stock.